Orphalan

Quick facts

Marketed products

• D-Penicillamine · Rheumatology / Toxicology
  D-Penicillamine is a chelating agent that binds to heavy metals and promotes their urinary excretion, while also modulating immune function through reduction of disulfide bonds.

Phase 3 pipeline

• Penicillamine (D1-W12) · Rare disease / Metabolic disorder
  Penicillamine is a chelating agent that binds to heavy metals and promotes their urinary excretion, reducing toxic metal accumulation in tissues.
• Penicillamine (W12-W60) · Rare disease / Metabolic disorder
  Penicillamine is a chelating agent that binds to heavy metals and promotes their urinary excretion, while also modulating immune responses through effects on collagen cross-linking and T-cell function.
• TETA 4HCL (60-<W108) · Cardiovascular
  TETA 4HCL is a tetraethylammonium chloride, a potassium channel blocker.
• TETA 4HCl formulation · Cardiovascular
  TETA 4HCl formulation is a tetraethylammonium chloride, a potassium channel blocker.
• TETA 4HCL (W12-60) · Cardiovascular
  TETA 4HCL (W12-60) is a tetraethylammonium chloride, a potassium channel blocker.

Phase 2 pipeline

• New TETA 4HCl Formulation

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Orphalan portfolio CI brief
• Orphalan pipeline updates RSS